Dedicated to deliver first-in-class medical devices and pharmaceuticals for local bone healing
OSTEO-PHARMA
LATEST NEWS
Osteo-Pharma BV was founded in 2014 and develops novel products for orthopedic and dental applications for the local treatment of bone fractures and bone defects. Products in development are based on our proprietary OsteoActivatorTM technology.
This technology involves encapsulating ancillary amounts of low molecular weight bone healing compounds in a biodegradable carrier resulting in a local sustained release of these compounds over a 4-6-week period. During this period bone formation is enhanced and bone resorption is inhibited simultaneously, resulting in a net effect of increased bone growth. Our lead product, OsteoActivator-P, has been approved by an accredited Medical Research Ethics Committee (MREC) and will be subject of a dental clinical study starting mid-2021 in the Netherlands. In addition, preclinical studies on improved bone fracture healing and the treatment of impaired bone remodeling in osteoarthritis are ongoing. Preclinical studies with OsteoActivator coated implants that improve osseo-integration to prevent implant loosening, have successfully been completed.
First Patient Treated in Clinical Study of OsteoActivator-P Membranes for Accelerated Alveolar Ridge Preservation
Osteo-Pharma today announced that the first patient has been treated for the clinical trial ‘OsteoActivator-P for accelerated localized alveolar ridge preservation’. The study is a randomized prospective clinical trial, comparing OsteoActivator-P coated membranes vs Collagen Membrane-P uncoated for accelerated localized alveolar ridge preservation and will investigate the efficacy and safety of OsteoActivator-P. The study is expected to enroll a total of 16 patients at 2 clinical centers in The Netherlands.
OSTEOACTIVATORTM TECHNOLOGY PLATFORM
Osteo-Pharma’s OSTEOACTIVATORTM technology is based on the use of EMA and FDA approved low molecular weight pharmaceuticals. By encapsulation in a biodegradable carrier sustained release of these pharmaceuticals over a 6-8 week period is obtained. During this period osteoblast activity is enhanced and osteoclast activity is inhibited resulting in a net shift towards the formation of new and stronger bone. Upon release of the therapeutics (after 6-8 weeks) bone remodeling will continue normally and, hence, the newly formed high quality bone will remain intact. Furthermore, the biodegradable carrier will degrade within the next few weeks eliminating the need for surgery to remove the carrier. read more
BONE FRACTURE FACTS
Bone fracture healing results in regeneration of bone at the fracture site resulting in bone tissue that has similar biomechanical competence as before the injury. Fractures, or broken bones, are extremely common. On average, every person will experience two broken bones over the course of a lifetime.read more